Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Biogen Idec CEO James Mullen: An Interview With “The Pink Sheet” DAILY

This article was originally published in The Pink Sheet Daily

Executive Summary

Company is “open for business” on deals, Mullen says during break at Massachusetts Biotechnology Council investor conference.

You may also be interested in...

Biogen Idec Looks To Develop PML Treatment

Alnylam’s RNAi technology will be directed at progressive multifocal leukoencephalopathy, the brain disease associated with Biogen’s MS therapy Tysabri.

Biogen Idec Will Move MS Therapy Into Phase III After Fumapharm Buy

Acquisition follows the release of positive Phase II study results of BG-12 in relapsing-remitting MS.

Biogen Idec Business Development Plan Includes Small Molecules For Oncology

The company expects the bulk of expenditures from a $200 mil. business development plan will go toward up-front milestones and new clinical costs for in-licensed drugs.


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts